Empirical treatment of febrile, neutropenic patients with tobramycin and latamoxef.
One hundred and two febrile episodes in neutropenic patients were treated with intravenous tobramycin and latamoxef. After 48 h latamoxef at 6 g day-1, patients were randomized to continue this regimen or latamoxef at 3 g day-1. Infections responded to these regimens in 67% and 71% of patients, respectively. Two-thirds of the infections which failed to respond were due to coagulase-negative staphylococci in Hickman catheters, a trend which may necessitate the inclusion of additional antibiotics in future empirical regimens. Prolonged prothrombin times due to antibiotic therapy were seen in nine patients but there was only one episode of bleeding and this responded quickly to treatment with vitamin K and fresh frozen plasma. In 35 patients, coagulopathy was present before antibiotics were started, and these cases also responded to vitamin K. The study shows that the response to tobramycin and latamoxef is comparable to other broad-spectrum antibiotic regimens and that a reduction in the dose of latamoxef after 48 h treatment may safely permit cost savings.
D000380:Agranulocytosis / Q000150:complications*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005334:Fever / Q000209:etiology; D006801:Humans; D007108:Immune Tolerance; D007945:Leukemia, Lymphoid / Q000150:complications; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D009070:Moxalactam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009503:Neutropenia / Q000150:complications*; D011517:Prothrombin Time; D011897:Random Allocation; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*
D009070:Moxalactam; D014031:Tobramycin